A Gringeri, E Santagostino, M Muça-Perja, H Le Buanec, B Bizzini, A Lachgar, J F Zagury, J Rappaport, A Burny, R C Gallo, D Zagury
Because administration of Tat protein, the HIV-1 toxin that induces immunosuppression and apoptosis, may be deleterious to the host immune system, a chemically inactivated but nonetheless immunogenic Tat preparation, Tat toxoid, was used to immunize seronegative individuals against Tat. In an open, controlled, phase I clinical trial, Tat toxoid turned out to be safe, well tolerated, and able to trigger a specific immune reaction. In particular, a threefold to more than 10-fold increase of circulating antibodies directed against the native Tat was observed after immunization in all of 5 immunized study subjects, together with a positive reaction to delayed-type hypersensitivity (DTH) skin test with Tat toxoid in vivo and increased lymphoproliferative response to native Tat in vitro...
April 1, 1999: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology